10-Q: Utah Medical Products Sales Decline in Q2 2026

Utah Medical Products Inc. reported a 14.3% decrease in Q2 2026 sales and an 11.9% drop in net income compared to the same period in 2025, primarily due to the loss of two major customers.

Summary

• Utah Medical Products Inc. (UTMD) reported a 14.3% decrease in net sales for the second quarter of 2026, totaling $8.5 million, compared to $9.9 million in Q2 2025.
• For the first six months of 2026, net sales decreased by 12.3% to $17.3 million from $19.7 million in the same period of 2025.
• Net income for Q2 2026 was $2.7 million, an 11.9% decrease from $3.0 million in Q2 2025.
• First half net income for 2026 was $5.3 million, down 13.1% from $6.1 million in the first half of 2025.
• The decline in sales is attributed to the loss of two major customers, representing a combined $1.07 million decrease in Q2 2025 sales and $1.92 million in the first half of 2025.
• The company maintained a strong balance sheet with no debt and ended the period with $87.5 million in cash and investments.
• Litigation costs increased significantly, impacting operating income.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to a significant decline in sales and net income compared to the prior year, despite stable profit margins and a strong balance sheet.

Positives

• Maintained a strong balance sheet with no debt.
• Ending cash and investments increased to $87.5 million from $85.8 million at the end of 2025.
• Gross profit margin remained relatively stable, at 55.8% in Q2 2026 compared to 56.2% in Q2 2025.
• Operating income margin remained healthy at 31.1% in Q2 2026.
• The company continues to return cash to stockholders through dividends and share repurchases.
• Management expects litigation expenses to decrease in the second half of 2026.

Negatives

• Net sales decreased by 14.3% in Q2 2026 and 12.3% in the first half of 2026 compared to the prior year periods.
• Net income decreased by 11.9% in Q2 2026 and 13.1% in the first half of 2026 compared to the prior year periods.
• Loss of two major customers significantly impacted sales, with zero sales to these entities in the first half of 2026.
• New product sales to other biopharma OEM customers did not develop as quickly as expected.
• Litigation costs increased by $213 million in Q2 2026 and $341 million in the first half of 2026 compared to the prior year.
• Average inventory turns declined to 1.7 in Q2 2026, below management targets.

Risks

• The company's sales projections for 2026 are unlikely to be met due to slower-than-expected new sales development.
• Continued substantial uncertainty exists regarding the company's 2026 sales outlook, with a projected decline of 10-13% compared to 2025.
• The company faces ongoing litigation related to the Filshie clip product liability.
• Tariffs on imported goods, particularly the Filshie Clip System manufactured in Ireland, negatively impacted gross profit margin.
• Potential reciprocal tariffs charged by other countries on goods sold by UTMD OUS may continue to negatively impact sales.
• The company's ability to easily change suppliers due to strict regulatory standards for medical devices limits flexibility in response to raw material price increases.

Future Outlook

Management's current year 2026 sales projection, with continued substantial uncertainty, is a sales decline of 10-13% compared to 2025. The company plans to realize new sales of high-pressure process control transducer configurations, regain OUS business hindered by trade policies, bring Filshie Clip System product liability lawsuits to a favorable conclusion, introduce additional products, achieve excellent financial operating performance, and utilize cash for dividends, share repurchases, or acquisitions.

Management Comments

• The lower sales in comparison with the prior years periods were primarily the result of a lack of sales to UTMDs two previously largest customers.
• Unfortunately, in 1H 2026 the new sales did not develop as quickly as expected, so that the beginning plan for 2026 full year revenues is now unlikely.
• Managements best guess now is that 2026 litigation expenses will be less than $1.6 million.
• Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans.
• The Company intends to utilize cash not needed to support normal operations in one or a combination of the following: 1) in general, to continue to invest at an opportune time in ways that will enhance future profitability; 2) to make additional investments in new technology and/or processes; and/or 3) to acquire a product line or company that will augment revenue and EPS growth and better utilize UTMDs existing infrastructure.
• If there are no better strategic uses for UTMDs cash, the Company will continue to return cash to stockholders in the form of dividends and share repurchases when the stock appears undervalued.

Industry Context

StockSavvy.ai notes that the decline in sales for Utah Medical Products Inc. is significantly impacted by the loss of major customers, a common challenge in the medical device sector where customer concentration can pose risks. The increased litigation costs also highlight a prevalent risk for companies in this industry.

Comparison to Industry Standards

• The company's gross profit margin of 55.8% in Q2 2026 is strong, but the decline in sales and net income is a concern. Industry benchmarks for gross margins in specialized medical devices can vary widely, but maintaining such a margin while sales decline suggests cost control efforts.
• The operating income margin of 31.1% is also robust, indicating efficient operations relative to sales volume. However, the increase in litigation expenses is a significant factor impacting profitability.
• The company's current ratio of 48.6 is exceptionally high, far exceeding typical industry standards for liquidity, indicating a very strong financial position.
• The debt-to-assets ratio of 2.0% is extremely low, suggesting minimal financial leverage, which is a conservative approach compared to many companies in the medical device industry that may use debt for growth.

Legal Proceedings

• The company is currently involved in Filshie clip product liability lawsuits. The outcome is not expected to be material to overall consolidated financial results.

Stakeholder Impact

• Shareholders: Reduced net income and EPS may impact shareholder returns. However, the company's commitment to dividends and share repurchases, along with a strong balance sheet, aims to maximize shareholder value.
• Employees: Increased litigation costs and sales decline could potentially impact future employment opportunities or compensation, though no specific impacts are mentioned.
• Customers: The loss of two major customers indicates a shift in the customer base, potentially affecting future sales dynamics.
• Suppliers: Increased raw material prices, partly attributed to tariffs, could impact the cost of goods sold and potentially lead to price adjustments if not absorbed.

Next Steps

• Continue to invest at opportune times in ways that will enhance future profitability.
• Make additional investments in new technology and/or processes.
• Acquire a product line or company that will augment revenue and EPS growth.
• Return cash to stockholders in the form of dividends and share repurchases if the stock appears undervalued.
• Continue to monitor and manage litigation expenses, with an expectation of lower costs in the second half of 2026.

Key Dates

Recommendation

While the company maintains a strong balance sheet and healthy margins, the significant decline in sales and net income due to customer loss and increased litigation costs warrants caution. The future outlook remains uncertain, making a 'hold' recommendation appropriate until sales recovery and litigation resolution become clearer.

Keywords

medical devices, obstetrics, gynecology, urology, neonatal, blood pressure monitoring, Filshie Clip System, OEM customers